In a mouse model of breast cancer, STING agonists promoted the activation of the STING/TBK1/IRF3/STAT1 pathway, releasing IFN-β, thereby enhancing the efficacy of the PD-L1 monoclonal antibody. Here, STING1 is linked to breast carcinoma.